Transition from reference adalimumab to biosimilar SB5 in patients with rheumatoid arthritis: sub-analysis of Spanish patients in the PROPER study DOI Creative Commons
Fernando Perez‐Ruiz,

B Paret,

Eugenio Chamizo Carmona

и другие.

Exploration of Musculoskeletal Diseases, Год журнала: 2025, Номер unknown

Опубликована: Фев. 10, 2025

This sub-analysis of the PROPER study aimed to evaluate outcomes following transition from reference adalimumab (ADL) SB5 (Imraldi™) in routine clinical practice Spanish patients with rheumatoid arthritis (RA). Adult (n = 73) RA who initiated as part treatment ADL were recruited. Outcome measures included persistence on SB5, characteristics, and disease activity scores at time treatment, management over time, safety. At Week 48, Kaplan-Meier [95% confidence interval (CI)] estimate probability after switching was 0.84 (0.73–0.90) 83.6% (46/55) remission or had low activity. The majority [83.6% (61/73)] experienced no flare during period reported that injection “simple very simple” administer (baseline: 66.7%; 48: 69.0%) generally “satisfied satisfied” duration injection. In total, 21 (21/73, 28.8%) least one drug-related adverse event, which mild most cases (17/21, 80.9%). a cohort transitioning high effectiveness maintained for up 48 weeks. There new safety signals well tolerated. These findings suggest there is evidence mitigate against (Clinicaltrials.gov listing: NCT04089514).

Язык: Английский

Transition from reference adalimumab to biosimilar SB5 in patients with rheumatoid arthritis: sub-analysis of Spanish patients in the PROPER study DOI Creative Commons
Fernando Perez‐Ruiz,

B Paret,

Eugenio Chamizo Carmona

и другие.

Exploration of Musculoskeletal Diseases, Год журнала: 2025, Номер unknown

Опубликована: Фев. 10, 2025

This sub-analysis of the PROPER study aimed to evaluate outcomes following transition from reference adalimumab (ADL) SB5 (Imraldi™) in routine clinical practice Spanish patients with rheumatoid arthritis (RA). Adult (n = 73) RA who initiated as part treatment ADL were recruited. Outcome measures included persistence on SB5, characteristics, and disease activity scores at time treatment, management over time, safety. At Week 48, Kaplan-Meier [95% confidence interval (CI)] estimate probability after switching was 0.84 (0.73–0.90) 83.6% (46/55) remission or had low activity. The majority [83.6% (61/73)] experienced no flare during period reported that injection “simple very simple” administer (baseline: 66.7%; 48: 69.0%) generally “satisfied satisfied” duration injection. In total, 21 (21/73, 28.8%) least one drug-related adverse event, which mild most cases (17/21, 80.9%). a cohort transitioning high effectiveness maintained for up 48 weeks. There new safety signals well tolerated. These findings suggest there is evidence mitigate against (Clinicaltrials.gov listing: NCT04089514).

Язык: Английский

Процитировано

0